Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks

Oral Abstract Session: Melanoma/Skin Cancers
Sunday, June 6, 2021; 8:00 AM–11:00 AM EDT

9501 Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma. KF Grossmann, M Othus, SP Patel, et al

Take-Home Message

  • The effectiveness of pembrolizumab for the treatment of patients with high-risk resected melanomas was compared with standard-of-care regimens (HDI or ipilimumab). Recurrence-free survival (RFS) was statistically improved in the pembrolizumab group (HR, 0.740; 99.618% CI, 0.571–0.958), while overall survival (OS) was not, both for the overall patient population (HR, 0.837; 96.3% CI, 0.622–1.297) and the PD-L1+ patient population (HR, 0.883; 97.8% CI, 0.604–1.291). HDI and ipilimumab were associated with higher rates of grade 3 adverse events (69% and 43%, respectively) than pembrolizumab (17%).
  • Compared with the standard-of-care regimens, pembrolizumab was better tolerated and improved RFS but not OS.

9503 Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). EJ Lipson, HA-H Tawbi, D Schadendorf, et al

Take-Home Message

  • This study evaluated whether a fixed-dose combination treatment targeting two potentially synergistic immune checkpoint pathways (LAG-3 and PD-1 by relatlimab and nivolumab, respectively) would provide a better benefit–risk profile than monotherapy. The relatlimab plus nivolumab group had significantly longer progression-free survival (PFS; 10.1 months) than the nivolumab group (4.6 months). However, it also had a higher rate of grade 3–4 treatment-related adverse events (18.9% vs 9.7%).
  • Compared with nivolumab alone, the relatlimab plus nivolumab fixed-dose combination had a significant PFS benefit, indicating that dual inhibition might be a promising strategy. The therapy was also well-tolerated, and the treatment-related adverse events were manageable.

9506 CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. JD Wolchok, V Chiarion-Sileni, R Gonzalez, et al

Take-Home Message

  • Patients with unresectable stage III or IV melanoma were treated with nivolumab (NIVO) plus ipilimumab (IPI), NIVO alone, or IPI alone. At the 6.5-year follow-up, NIVO + IPI was associated with longer median overall survival (OS; 72.1 months for the combination vs 36.9 months for NIVO and 19.9 months for IPI), a longer median treatment-free interval (27.6 months vs 2.3 months and 1.9 months), a lower percentage of patients who received subsequent systemic therapy (36% vs 49% and 66%), and a higher percentage of patients who were off treatment and never received subsequent therapy (81% vs 74% and 43%). However, more grade 3/4 treatment-associated adverse events were reported for the NIVO + IPI group (59%) than the other two groups (24% for NIVO and 28% for IPI).
  • There was an increased benefit in using NIVO + IPI versus NIVO or IPI alone in terms of overall survival, progression-free survival, and objective response rate.


Click here to visit this article on PracticeUpdate’s website to learn more.